CO-THERAPY COMPRISING A SMALL MOLECULE CSF-1R INHIBITOR AND AN AGONISTIC ANTIBODY THAT SPECIFICALLY BINDS CD40 FOR THE TREATMENT OF CANCER

The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageEnglish
Published 02.03.2018
Online AccessGet full text

Cover

More Information
Summary:The present invention is directed to methods for treating cancer, preferably a solid tumor or hematological malignancy, including for example pancreatic cancer, lung cancer (including but not limited to non-small cell lung cancer (NSCLC)), prostate cancer, colorectal cancer, breast cancer, melanoma or non-Hodgkin's lymphoma, comprising administering to a subject in need thereof a therapeutically effective amount of co-therapy comprising, consisting or consisting essentially of (a) a small molecule CSF-1R inhibitor and (b) an agonistic antibody that binds CD40.